[Association between SCN1A rs3812718 polymorphism and generalized epilepsy with febrile seizures plus]

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Epilepsy Research

Background:

• Generalized epilepsy with febrile seizures plus (GEFS+) is a severe form of childhood epilepsy.
• Genetic factors play a crucial role in the pathogenesis of GEFS+.
• The SCN1A gene encodes the alpha subunit of the Nav1.1 voltage-gated sodium channel, critical for neuronal excitability.

Purpose of the Study:

• To investigate the association between the SCN1A rs3812718 polymorphism and the risk of developing GEFS+.
• To identify potential genetic markers for GEFS+ diagnosis.
• To explore molecular targets for GEFS+ treatment.

Main Methods:

• Genotyping of the SCN1A rs3812718 polymorphism using the iPLEX technique on the MassARRAY system.
• Comparison of genotype and allele frequencies between 50 GEFS+ patients and 50 healthy controls.
• Statistical analysis including odds ratio (OR) and 95% confidence intervals (CI) to assess risk.

Main Results:

• A significant difference in the TT genotype frequency of SCN1A rs3812718 was observed between the GEFS+ and control groups (P<0.05).
• The T allele frequency was also significantly higher in the GEFS+ group compared to controls (P<0.05).
• Individuals with CT or TT genotypes, or the T allele, exhibited a significantly increased risk of GEFS+ (e.g., TT/CC: OR=30.60, 95%CI: 6.46-144.85).

Conclusions:

• The SCN1A rs3812718 polymorphism is identified as a significant risk factor for GEFS+.
• Carrying the T allele of SCN1A rs3812718 confers an elevated risk of developing GEFS+.
• This polymorphism may serve as a valuable biomarker for GEFS+ susceptibility.